Bilateral breast cancer is one of the risk-enrichment criteria for BRCA1/2 mutation in the Pen II risk model [1], BRCAPRO [2], and NCCN guidelines [3] to select appropriate patients indicated for germline mutation testing. This evidence concerns the gene BRCA1 and breast carcinoma.